An Exploratory, Multicenter, Randomized, Double Blind Study of Clinical Outcomes, Tolerability, and Safety of 2 Doses of Oral Pantoprazole In Pediatric Participants Aged 1 to 11 Years and 12 to 17 Years Who Require Maintenance Therapy for Healed Erosive Esophagitis
Latest Information Update: 24 Jun 2025
At a glance
- Drugs Pantoprazole (Primary)
- Indications Erosive oesophagitis
- Focus Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 15 Jun 2025 Planned End Date changed from 9 Dec 2027 to 9 May 2030.
- 15 Jun 2025 Planned primary completion date changed from 9 Dec 2027 to 9 May 2030.
- 15 Jun 2025 Status changed from recruiting to active, no longer recruiting.